The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The budget confirms digital expansion in the NHS
Just seen Stuart’s LinkedIn post worth reading albeit quite difficult to fully comprehend!
Hemcheck Sweden AB
Press release
Notice of Extraordinary General Meeting in Hemcheck Sweden AB (publ)
The shareholders of Hemcheck Sweden AB, org.nr 556811-5272 ("Hemcheck" or the "Company"), are hereby summoned to the Extraordinary General Meeting to be held on Friday 24 November 2023 at 11:00 a.m. at Nanna Svartz väg 2 in Solna, Sweden. Registration for the meeting will commence at 10.30 a.m.
Exercise of voting rights at the meeting
Shareholders who wish to participate in the Annual General Meeting must
be recorded in the share register maintained by Euroclear Sweden AB on Thursday 16 November 2023, and
notify the Company of their intention to participate in the general meeting in accordance with the instructions set out in the section "Notification of attendance for participation in person or by proxy" in such time that the notification is received by the Company no later than Monday 20 November 2023.
Nominee-registered sharesr
Shareholders whose shares are registered in the name of a nominee must, in order to exercise their voting rights, notify the Company of their intention to participate in the Annual General Meeting and request to temporarily register the shares in their own name in the share register maintained by Euroclear. Such registration must be completed no later than Monday 20 November 2023 and shareholders must therefore inform their nominees well in advance of this day. Voting registration that has been requested by the shareholder at such time that the registration has been completed by the nominee no later than Monday 20 November 2023 will be taken into account in the preparation of the share register.
Notice of attendance for attendance in person or by proxy
Shareholders who wish to participate in the general meeting in person or by proxy must notify the Company of their intention to attend the meeting no later than Monday 20 November 2023 either:
by e-mail to info@hemcheck.com, or
by mail to Hemcheck Sweden AB, Nanna Svartz väg 4, 171 65 Solna, Stockholm (mark the envelope "EGM 2023").
The notification shall state name or company name, personal identification number or corporate registration number, address, telephone number and, where applicable, the number of assistants (maximum two).
Shareholders who do not wish to attend in person may exercise their rights at the meeting through a proxy with a written, signed and dated power of attorney. If the power of attorney is issued by a legal entity, a copy of the certificate of registration or equivalent document of authority for the legal entity must be attached.
In order to facilitate the entrance to the general meeting, powers of attorney, certificates of registration and other documents of authority should be received by the Company at the address Hemcheck Sweden AB, Nanna Svartz väg 4, SE-171 65 Solna, Stockholm (mark the envelope "EGM 2023") well in advance of the general meeting and preferably no later than Monday 20 November 2023.
P
Https://view.news.eu.nasdaq.com/view?id=bd8b6954aad29239377b5e90a588c9298&lang=sv&src=micro
Notice a typo should be 28,000,000
Looking back at a recent portfolio update Stormfjord Ltd and Rosedog both raise funds at a valuation of $2800000 so you would assume any conversion to shares would be based on these valuation otherwise the investors would not be too happy.
A few observations
If CRV are willing to selling their 29% then assume the remaining parties are also willing to sale and achieve a main London listing
Looking back at a recent portfolio update Stormfjord Ltd and Rosedog both raise funds at a valuation of $2800000 so you would assume any conversion to shares would be based on these valuation otherwise the investors would not be too happy.
One would hope the e commerce companies have a growth strategy upon listing which will be announced once any agreements have been reached, interesting times !
We also have the Hemcheck listing and their plans to expand the Bio Vitos portfolio which again could provide a good return
Just have to wait as this all unfolds
Extract of previous portfolio update below
The Company has been informed that Stormfjord, the owner of www.onebas.com raised $100,000 on 1st March 2023 at a valuation of $28,000,000.
Craven House originally acquired a 29.9% stake in Onebas.com Ltd (the previous legal entity under which the domain Onebas.com was owned) on 13 March 2020 for a consideration of $1,600,000 via a share subscription for 800,000 ordinary shares in the Company priced at $10.00 per share. This valued Onebas.com Ltd at $5.35m.
Following completion of the fundraising, Craven House's holding of 29,900,000 shares represents 25.5% of Stomfjord.
Rosedog Ltd ("Rosedog")
The Company has been informed that Rosedog, the owner of www.tvzinos.com raised $70,000 on 1st March 2023 at a valuation of $28,000,000.
Craven House originally acquired a 29.9% stake in Rosedog on 13 March 2020 for a consideration of $1,600,000 via a share subscription for 800,000 ordinary shares in the Company priced at $10.00 per share. This valued Rosedog Ltd at $5.35m.
Following completion of the fundraising, Craven House's holding of 29,900,000 shares represents 28.6% of Rosedog.
There is a need, due to passage of time to update the Share Purchase Agreement (former Class two members). Those affected will receive an email shortly of changes requested by the regulators.
The Company has now started the process of Stock Exchange review (TSXV). The Company will seek a derogation not to have a regulated Sponsor as the prospectus is a non-offering prospectus (not raising capital at listing). There is no certainty we will be given a derogation and if not, the appointment and review of a sponsor can take up to three months.
Patent Application and ?Approvals?
The Company’s specialist patent attorney, Office Freylinger Luxembourg, has advised that in addition to those patents that have been granted and official patent certificates issued for the “Catheter System for Continuous Irrigation” significant progress has been made., the remaining 21 patent applications based on PCT/US2017/026450 theatre still being assessed and reviewed in the individual countries.
PureFlowCath Prototype Design and Manufacture
Management is pleased to advise that Paragon Medical (www.paragonmedical.com) has made significant progress inr the design, engineering and prototype testing of the continuous flow catheter. Further work has also commenced on packaging and production of a functional prototype.
All work will be performed in accordance with “ISO 1485:2016 – Quality Management Systems – Requirements for regulatory purposes” and “21 CFR Part 820 – Quality System Regulations”.
FDA Approval Strategy and Appointment of FDA Specialist Clark Regulatory Solutions, LLC
Management concluded an agreement with Clark Regulatory Solutions, LLC to assist with the planning and execution of our regulatory strategy to guide us through the FDA regulatory processes in the most expeditious way as we work concurrently with Paragon Medical on the development of a prototype.
www.InnomedTec.com
Billy Williams Disclosure Officer/Director +1 251 786 4695 BWilliams@InnomedTec.com
CORPORATE UPDATE JUNE 15, 2022
InnoMed Tech Ltd is holding Company of medical science companies in the business of creating paradigm shifts in thinking to improve clinical outcomes for medical and surgical patients. The Company’s clinical and business leadership team combines years of experience of corporate, and medical science who along with medical engineers, key advisors, work to solve problems presenting in today’s medical and surgical patient population.
Directors Innomed Tec Ltd. (Parent Co):
Robert L. Rhodes - Australia (CEO)
Terrance A. Larkan - Australia (CFO)
Billy Williams - US
David Toyoda - Canada
Dr Marshall Walker- US
Directors PureFlowCath LLC. (US):
Dr Matthew Mcintyre
Robert L. Rhodes
3 to 2 independent directors
Summary of Operations
InnoMed Tech Ltd. (the “Company”) is ?pleased to provide an update on some of the corporate activities and outcomes since the last update on April 4, 2022.
The Company is now concluding the initial debt finance of Euro €10,000,000 to ensure the Company Tech complies with 12-month working capital requirements for prospectus approval. An initial sum is likely to be drawn down before final prospectus approval.
The debt finance has an option for the note holder to convert to equity at same terms as the equity subscription that would result in dilution of current shareholders. Dilution refers to a shareholder’s percentage ownership decreasing as a result of new shares being issued.
CIC Capital Ltd.’s Stuart J. Bromley, Transaction Advisor to the Company, will be emailing every cash subscriber directly with the transaction disclosure documents and an offer same terms; a statutory requirement of any Canadian Issuer.
Since the initial subscription in April 2020 which ushered in a new board and management team, , significant progress has been made in the independent auditing of 3 full years plus interims, completion of administrative requirements for the public listing process, securitisation of patents/applications, prototype design/manufacture and agreement of the FDA device approval strategy. Based on the work done we believe that it is very likely that by peer pricing, the listed price will, in the medium term, be significantly higher than the subscribed pricing of US 29 cents per share.
The debt finance through Luxembourg Securitisation (www.Securitisation.com) is now being concluded, facilitated by the progress made since April 2020 and the advanced stage for regulatory approval of the prospectus.
The debt finance by Luxembourg Securitisation (www.Securitisation.com) is now being concluded due to the advanced stage of regulatory approval of the prospectus.
TSX Venture Exchange Listing Update
The Company’s latest prospectus is attached to this corporate update, dated June 14, 2022.
There is a need, due to passage of time to update the Share Pu
CIC Securitization is owned by Stuart Bromley which has nothing to do with CIC Fund, CIC Capital is assisting CIC securitization and earning a fee which hopefully will enable them to float and pay shareholders dividends
Let's hope we have the same trajectory ! Market Summary
>
Caerus Mineral Resources PLC
26.25 GBX
+13.25 (101.92%)past year
Corporate update received tonight
https://www.londonstockexchange.com/news-article/market-news/corporate-update/14924191?lang=en
Did this corporate update get posted?
Div yield -
Prev close 1.73
52-wk high 66.50
52-wk low 0.47
looking at the technical reports from CIC gold website and Kiincora site the location of the exploration is the same both shown just above Tsagaan Suvarga Cu Au deposit. So is this a joint venture or have we sold our interest and taken an option out on future profits ????
Doesn't take many shares to move the bid though
https://web.tmxmoney.com/pricehistory.php?qm_symbol=DLC
I must admit you do go on and on and on about how bad things, take a break for god's sake man !!! They completed the two year contract that is not a lost contract, anyone would think you have an alternative agenda to drive the share price down, maybe to pick up cheaper shares !!! Lets hope they pick up a few large contracts and see how that affects the share price and outlook